Implantica AG engages in the research and distribution of medical implants in Switzerland and Spain. The company's lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system monitor, transmit, and actively treat conditions from within the body; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, the company develops UriControl, a hand pumped artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform. Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for monitoring the expansion of the aneurysms. The company was founded in 2015 and is based in Vaduz, Liechtenstein.
Research context
Implantica AG appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
No comments yet
Start a focused discussion about 8IM1.F.